NCT01757171View on ClinicalTrials.gov

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

June 30, 2017

Conditions
Gastric AdenocarcinomaGastroesophageal AdenocarcinomaDistal Esophageal Adenocarcinoma
Interventions
DRUG

Cabazitaxel

20mg IV over 1 hour every 3 weeks

Trial Locations (5)

10065

Weill Cornell Medical College, New York

48201

Karmanos Cancer Institute, Detroit

94115

UCSF Comprehensive Cancer Center, San Francisco

06510

Yale University, New Haven

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT01757171 - Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter